These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 14718800)

  • 1. Neurotoxicity of taxanes: symptoms and quality of life assessment.
    Kuroi K; Shimozuma K
    Breast Cancer; 2004; 11(1):92-9. PubMed ID: 14718800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taxane induced neuropathy in patients affected by breast cancer: Literature review.
    De Iuliis F; Taglieri L; Salerno G; Lanza R; Scarpa S
    Crit Rev Oncol Hematol; 2015 Oct; 96(1):34-45. PubMed ID: 26004917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early taxane exposure and neurotoxicity in breast cancer patients.
    Cimbro E; Dessì M; Ziranu P; Madeddu C; Atzori F; Lai E; Pretta A; Mariani S; Donisi C; Spanu D; Pozzari M; Murgia S; Saba G; Codipietro C; Palmas E; Sanna G; Semonella F; Sardo S; Finco G; Scartozzi M
    Support Care Cancer; 2024 Oct; 32(10):709. PubMed ID: 39375221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of taxane neurotoxicity.
    Hagiwara H; Sunada Y
    Breast Cancer; 2004; 11(1):82-5. PubMed ID: 14718798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expert consensus on standardized management of taxane-related peripheral neuropathy].
    Taxane-related Peripheral Neuropathy Standardized Management Group
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):170-179. PubMed ID: 32252195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Techniques for the neurological examination of taxane-induced neuropathy.
    Ohsumi S; Sunada Y
    Breast Cancer; 2004; 11(1):86-91. PubMed ID: 14718799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment.
    Tamburin S; Park SB; Alberti P; Demichelis C; Schenone A; Argyriou AA
    J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S40-S51. PubMed ID: 31647157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies.
    Park SB; Krishnan AV; Lin CS; Goldstein D; Friedlander M; Kiernan MC
    Curr Med Chem; 2008; 15(29):3081-94. PubMed ID: 19075655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment and care of neurotoxicity from taxane anticancer agents.
    Makino H
    Breast Cancer; 2004; 11(1):100-4. PubMed ID: 14718801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Taxane-induced polyneuropathy - current possibilities of prediction and management].
    Jablonická M; Žideková L; Mladosievičová B
    Vnitr Lek; 2021; 67(1):26-31. PubMed ID: 33752398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality-of-life considerations with taxane-based therapy in metastatic breast cancer.
    Maxwell C
    Clin J Oncol Nurs; 2013 Feb; 17 Suppl():35-40. PubMed ID: 23360701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case report: painful peripheral neuropathy following treatment with docetaxel for breast cancer.
    Wampler MA; Hamolsky D; Hamel K; Melisko M; Topp KS
    Clin J Oncol Nurs; 2005 Apr; 9(2):189-93. PubMed ID: 15853162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure.
    Driessen CM; de Kleine-Bolt KM; Vingerhoets AJ; Mols F; Vreugdenhil G
    Support Care Cancer; 2012 Apr; 20(4):877-81. PubMed ID: 22160655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer.
    Rivera E; Cianfrocca M
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):659-70. PubMed ID: 25596818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires.
    Zedan AH; Vilholm OJ
    Basic Clin Pharmacol Toxicol; 2014 Aug; 115(2):193-200. PubMed ID: 24796774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrophysiological and phenotypic profiles of taxane-induced neuropathy.
    Timmins HC; Li T; Huynh W; Kiernan MC; Baron-Hay S; Boyle F; Goldstein D; Park SB
    Clin Neurophysiol; 2020 Aug; 131(8):1979-1985. PubMed ID: 32291143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral nerve damage associated with administration of taxanes in patients with cancer.
    Argyriou AA; Koltzenburg M; Polychronopoulos P; Papapetropoulos S; Kalofonos HP
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):218-28. PubMed ID: 18329278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.
    Pronk LC; Hilkens PH; van den Bent MJ; van Putten WL; Stoter G; Verweij J
    Anticancer Drugs; 1998 Oct; 9(9):759-64. PubMed ID: 9840720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral neurotoxicity induced by docetaxel.
    Hilkens PH; Verweij J; Stoter G; Vecht CJ; van Putten WL; van den Bent MJ
    Neurology; 1996 Jan; 46(1):104-8. PubMed ID: 8559354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.